Ozanimod, sold under the brand name Zeposia, is an oral immunomodulator used to treat relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome (CIS), relapsing-remitting MS (RRMS), and active secondary progressive MS (SPMS). It works by selectively binding to sphingosine-1-phosphate (S1P) receptors, preventing immune cells from attacking the nervous system, thereby reducing inflammation and nerve damage. Ozanimod is also approved for ulcerative colitis (UC), where it helps control inflammation in the digestive tract.
Parent: Ozanimod Hydrochloride / Ozanimod
Like other pharmaceutical compounds, Ozanimod may contain impurities that need strict monitoring for safety and efficacy.
Related Substances
These include byproducts from synthesis that share a structural similarity with Ozanimod but may affect its activity and safety.
Degradation Products
Ozanimod may degrade over time, forming impurities due to oxidation, hydrolysis, or heat exposure, impacting its effectiveness.
Residual Solvents
Solvents used during the manufacturing process can remain in trace amounts, requiring stringent regulatory limits for safety.
Heavy Metals
Trace levels of heavy metals may be present due to raw materials or manufacturing processes, necessitating regular quality control checks.
Analytical Techniques for Impurity Detection
Techniques like High-Performance Liquid Chromatography (HPLC) and Mass Spectrometry (MS) are used to identify and quantify impurities in Ozanimod formulations.
Ozanimod may take 8 to 12 weeks to show its full effects in multiple sclerosis (MS) and ulcerative colitis (UC) patients.
Clinical studies have shown that Ozanimod significantly reduces the frequency of MS relapses and helps improve ulcerative colitis symptoms, leading to better disease management.
Yes, Ozanimod is an immunomodulator that selectively reduces the activity of immune cells, helping to prevent inflammation in MS and UC.
Zeposia is the brand name for Ozanimod, used to treat multiple sclerosis (MS) and ulcerative colitis (UC) by modulating the immune response to prevent excessive inflammation.
